Why the study?
Ticagrelor emerged as a potential alternative to overcome delayed onset of action in patients unable to swallow or with impaired absorption.
What is the pharmacokinetic and pharmacodynamic impact of different modes of ticagrelor administration in patients unable to swallow or with impaired absorption?
What is the pharmacokinetic and pharmacodynamic impact of different modes of ticagrelor administration in patients unable to swallow or with impaired absorption?
Alternative modes of ticagrelor administration, such as crushed tablets, may be limited by concomitant opioid use which impairs its action.
Answers are grounded in this paper and cite their sources.
Caution against crushed ticagrelor with opioids in ACS; confirms interaction limiting alternative administration routes.
INTRODUCTION: inhibitors, particularly ticagrelor, have emerged as a potential alternative to overcome the limitations associated with the delayed onset of action of these drugs in patients who are unable to swallow or with impaired absorption. AREAS COVERED: administration. For this purpose, Embase, Medline, Web of Science Core Collection, Cochrane Central Register of Controlled Trials, Google Scholar, and ClinicalTrials.gov were searched from database inception to July 2023. EXPERT OPINION: inhibitors such as cangrelor, and the important limitations associated with the concomitant use of opioids, who have been proven to impair even the action of crushed ticagrelor.
No takes yet. Share an insight, caveat, or question.
Spagnolo et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: